Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DKL13E
|
|||
Drug Name |
CPI-006
|
|||
Drug Type |
Antibody
|
|||
Indication | Advanced cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | |
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [2] | ||
Company |
Corvus Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Ecto-5'-nucleotidase (CD73) | Target Info | . | [3] |
BioCyc | Purine nucleotides degradation | |||
Urate biosynthesis/inosine 5'-phosphate degradation | ||||
Adenosine nucleotides degradation | ||||
KEGG Pathway | Purine metabolism | |||
Pyrimidine metabolism | ||||
Nicotinate and nicotinamide metabolism | ||||
Metabolic pathways | ||||
Panther Pathway | Purine metabolism | |||
Pyrimidine Metabolism | ||||
Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
Reactome | Purine catabolism | |||
WikiPathways | Differentiation Pathway | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in epithelium - TarBase | ||||
Metabolism of nucleotides |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | ClinicalTrials.gov (NCT03454451) CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers. U.S. National Institutes of Health. | |||
REF 3 | Clinical pipeline report, company report or official report of Corvus Pharmaceuticals. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.